UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-38943 Personalis, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 27-5411038 (State or ...

Financial Data and Key Metrics Changes - Revenues for Q2 2020 were $19.5 million, up 23% from $15.8 million in the same period last year, marking a new record high for quarterly revenues [33][41] - Gross margin improved to 24% from 21.1% in the prior quarter, despite a negative impact of approximately 80 basis points from COVID-19 related higher labor costs [36][41] - Net loss for Q2 was $9.3 million, compared to a net loss of $5.9 million for the same period last year, with a net loss per share of $0.29 [41][43] Business Line Data and Key Metrics Changes - The company sequenced about 14,000 whole human genomes in Q2, a 70% increase from Q2 last year [8] - Revenue from the NeXT platform exceeded $2 million in Q2, contributing to overall revenue growth despite a decline from biobank customers [34] - Revenue from pharmaceutical customers increased by more than 20% sequentially, offsetting declines from biobank and biotech customers [10][33] Market Data and Key Metrics Changes - VA MVP revenue was $14.8 million, flat from the prior quarter but up 73% from $8.5 million in the same period last year [35] - Unfulfilled orders from the VA MVP at the end of Q2 totaled $39.3 million, expected to convert to revenue over the next two to three quarters [35] Company Strategy and Development Direction - The company is expanding its liquid biopsy product line, which is designed to complement its tissue biopsy offerings, enhancing its competitive position [11][14] - A new lab and commercial operations are being established in China to support international pharmaceutical companies conducting clinical trials [18][20] - The company aims to leverage its experience with the VA MVP program to explore new opportunities in population sequencing globally [23][91] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in long-term growth, citing strong order levels from biopharma customers and the successful launch of the NeXT Liquid Biopsy [15][30] - The company anticipates challenges due to the ongoing pandemic but remains optimistic about future revenue streams and product adoption [43][30] Other Important Information - The company has expanded its commercial team in the U.S. and Europe to engage with more biopharma companies for potential companion diagnostic development [20] - The population sequencing business is on track to reach 100,000 whole human genome sequences by the end of the year, a significant milestone [21] Q&A Session Summary Question: Integration of electronic health record data with VA MVP project - Management confirmed that the VA MVP has a significant advantage due to the integration of electronic health records, which are already in electronic format [46][50] Question: Strategy for partnership with Berry Genomics in China - The company aims to set up sequencing capabilities in China to comply with local regulations, driven by requests from international pharmaceutical customers [51] Question: Differentiation of the liquid biopsy program in the market - The liquid biopsy product is designed to be used alongside tissue biopsy, providing comprehensive data across all 20,000 human genes, which is a significant differentiator [56][58] Question: Average order size and contract structure for NeXT - Orders typically cover all samples collected during clinical trials, which can be hundreds or even thousands of samples, with some contracts set up as blanket orders [66][68] Question: Impact of increased enrollment in the VA MVP - The increase in target enrollment to 2 million is expected to take about 10 years, with ongoing support for the program anticipated [81][84]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-38943 Personalis, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 27-5411038 (State or othe ...

Personalis, Inc. (NASDAQ:PSNL) Q1 2020 Earnings Conference Call May 7, 2020 5:00 PM ET Company Participants Caroline Corner – Westwicke ICR John West – President and Chief Executive Officer Aaron Tachibana – Chief Financial Officer Conference Call Participants Subbu Nambi – Cowen & Company Kevin DeGeeter – Oppenheimer Operator Ladies and gentlemen, thank you for standing by, and welcome to the Q1 2020 Personalis Earnings Conference Call. At this time, all participant lines are in listen-only mode. After the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-38943 Personalis, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 27-5411038 (State or oth ...

Personalis, Inc. (NASDAQ:PSNL) Q4 2019 Earnings Conference Call March 25, 2020 5:00 PM ET Company Participants Caroline Corner - Westwicke ICR John West - President and CEO Aaron Tachibana - CFO Clinton Musil - Chief Business Officer Conference Call Participants Derik De Bruin - Bank of America Merrill Lynch Doug Schenkel - Cowen & Company Kevin DeGeeter - Oppenheimer Operator Ladies and gentlemen, thank you for standing by, and welcome to the Fourth Quarter 2019 Personalis Earnings Conference Call. At this ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38943 Personalis, Inc. (Exact name of Registrant as specified in its Charter) | Delaware | 27-5411038 | | --- | --- | | (State or other jurisdic ...

Personalis, Inc. (NASDAQ:PSNL) Q3 2019 Earnings Conference Call November 13, 2019 5:00 PM ET Company Participants Caroline Corner - Westwicke John West - President & CEO Aaron Tachibana - CFO Clinton Musil - Chief Business Officer Conference Call Participants Yih-Ming Tu - Morgan Stanley Xiaoxiao Ma - Bank of America Doug Schenkel - Cowen & Company Kevin DeGeeter - Oppenheimer Operator Ladies and gentlemen, thank you for standing by and welcome to the Third Quarter 2019 Personalis Earnings Conference Call. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-38943 Personalis, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 27-5411038 (State or ...

Personalis, Inc. (NASDAQ:PSNL) Q2 2019 Earnings Conference Call August 13, 2019 5:00 PM ET Company Participants Caroline Corner - IR John West - President & CEO Aaron Tachibana - CFO Clinton Musil - Chief Business Officer Richard Chen - Chief Scientific Officer Conference Call Participants David Lewis - Morgan Stanley Derik De Bruin - Bank of America Merrill Lynch Doug Schenkel - Cowen Kevin DeGeeter - Oppenheimer Operator Welcome to the Q2 2019 Personalis Earnings Conference Call. [Operator Instructions]. ...